Biotechnology
JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina has approv...
2024-08-27 17:00
2441
Constellar and MY Exhibition Forge Strategic Partnership to Boost Agri-Food Technology and Aquaculture in Singapore and Taiwan region
SINGAPORE, Aug. 27, 2024 /PRNewswire/ -- Constellar and MY Exhibition Co., Ltd are pleased to announce a strategic partnership to boost the agri-food tech and aquaculture sectors inSingapore and Taiwan region. This collaboration will contribute to the broader goal of leveraging technology to adva...
2024-08-27 14:00
15345
Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence, Highlighting Agility, Responsiveness, Customer Value, and Proven Ability to Expedite Quality Clinical Programs
Avance Clinical streamlines its biotech clients' clinical trial operations, workflows, and data management, optimizing study efficiencies,minimizing costs, and accelerating trial timelines. SAN ANTONIO, Aug. 27, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the biotech contract researc...
2024-08-27 11:30
1325
ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment
BEIJING, Aug. 27, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr.Jim Wu, Chief Executive Officer of ArkBio, gave an oral presentation entitled"Development of Next Generation Broadly Activ...
2024-08-27 09:00
1832
CStone Reports 2024 Interim Results and Recent Corporate Updates
* Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash reserve atRMB 814 million as of June 30, 2024. * NDA approval of sugemalimab (PD-L1) for Stage IV NSCLC in EU, marking the first successful international approval of aChina domestic anti-PD-L1 mAb. ...
2024-08-23 22:20
6905
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization
SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announced its interim results for the period endingJune 30, 2024 , along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, stated, "In the...
2024-08-23 12:32
3823
Inaugural Process Innovation Asia Pacific to Drive Industry Transformation for South-East Asia's Chemicals and Pharmaceuticals
SINGAPORE, Aug. 22, 2024 /PRNewswire/ -- Organised by Constellar, in partnership with DECHEMA Ausstellungs-GmbH (DECHEMA Exhibitions)[1], the inauguralProcess Innovation Asia Pacific - Powered by ACHEMA (PIA) will be held from19 to 21 November 2024 at Singapore EXPO. The most comprehensive Pr...
2024-08-22 15:30
9367
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiat...
2024-08-22 08:00
2076
China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China
SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-08-22 08:00
3131
Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption
New Veeva Pulse findings show congresses and early-career experts have the
strongest influence on patient outcomes
SINGAPORE, Aug. 21, 2024 /PRNewswire/ -- Veeva Systems
2024-08-21 09:00
2867
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Aug. 20, 2024 /PRNewswire/ -- On August 20, the new drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) based on the positive results from the pivotal OptiTROP-Lung03 study has been accepted by the Center for Drug Evaluation (CDE)...
2024-08-20 16:32
1686
Allozymes and Adisseo Partner on Next-Gen Animal Feed Production Using Rapid Microfluidics Technology
SINGAPORE, Aug. 19, 2024 /PRNewswire/ -- Allozymes, a leading innovator in enzyme discovery and engineering, today announces a strategic partnership with Adisseo, one of the world's leading animal nutrition companies, to develop groundbreaking bioprocesses for animal feed ingredient production. T...
2024-08-19 15:57
1846
Ainex Unveils Advanced Endoscopy AI System at GIHEP & Singapore Hepatology Conference 2024
SINGAPORE, Aug. 19, 2024 /PRNewswire/ -- Ainex Corporation, a leading innovator in medical technology, has unveiled its advanced Endoscopy AI system, ENAD (Endoscopy as AI-powered Device), at the Combined GIHEP & Singapore Hepatology Conference 2024. This prestigious event, bringing together glob...
2024-08-19 08:01
2167
Alphamab Oncology Reports 2024 Interim Results and Business Highlights
SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months endedJune 30, 2024 and highlighted recent business progress. Financial Summary * For the six months ended June 30, 2024, we recorded total revenue of RMB ...
2024-08-16 11:18
3437
Cresilon Receives FDA Clearance for TRAUMAGEL
Hemostatic gel designed to control moderate to severe bleeding in seconds and save lives NEW YORK, Aug. 15, 2024 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn -based biotechnology company focused on hemostatic medical device technologies, today announced it has received U.S. Food and Dru...
2024-08-15 20:45
2129
NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT
HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biop...
2024-08-15 13:43
1854
NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovations
* The collaboration focuses on offering guidance, mentorship, and access to
expertise to the start-ups housed within NSG Biolabs SINGAPORE, Aug. 15, 2024
/PRNewswire/ --NSG BioLabs
2024-08-15 10:00
2694
Australian biotech incubator Proto Axiom announces $20M Series B first close
$20M unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at$90M SYDNEY, Aug. 13, 2024 /PRNewswire/ -- Proto Axiom, the Australian biomedical technology incubator has today announced a$20 million first close of its targeted$30 million Series B, to bolster Australia's...
2024-08-13 10:21
2685
Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE
ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for malignancies, announced today it has been cleared by the Ce...
2024-08-13 09:52
2268
Pantai Hospital Kuala Lumpur Introduces Outpatient Parenteral Antimicrobial Therapy (OPAT) for Improved Patient Care
KUALA LUMPUR, Malaysia, Aug. 12, 2024 /PRNewswire/ -- Pantai Hospital Kuala
Lumpur (PHKL) has officially introduced its Outpatient Parenteral Antimicrobial
Therapy (OPAT) service, offering an innovative treatment option that enhances
patient care.
2024-08-13 08:53
1997
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 307 media titles]
2025-01-06 14:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 292 media titles]
2025-01-06 19:25
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
17661
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
2025-01-07 09:00
5136
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
2025-01-06 14:00
4787